{
    "nct_id": "NCT04106219",
    "official_title": "A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma",
    "inclusion_criteria": "* Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.\n* Participants must be able to swallow capsules.\nHealthy volunteers allowed\nMust have minimum age of 2 Years\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.\n* Participants must not have untreated tumor that has spread to the brain or spinal cord.\n* Participants must not have a serious active disease other than neuroblastoma.\n* Participants must not have a condition affecting absorption.\n* Participants must not have had prior aurora kinase inhibitor exposure.\n* Participants must not have a known allergy to the study treatment.\n* Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.",
    "miscellaneous_criteria": ""
}